Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.
about
STAT proteins - key regulators of anti-viral responses, inflammation, and tumorigenesis in the liverIL-6 regulates Mcl-1L expression through the JAK/PI3K/Akt/CREB signaling pathway in hepatocytes: implication of an anti-apoptotic role during liver regenerationSorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant.A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma.Regulators of Cholangiocyte Proliferation.Histamine regulation of hyperplastic and neoplastic cell growth in cholangiocytes.Recent advances in the regulation of cholangiocarcinoma growthA smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cellsDifferential gene expression profiling of cultured neu-transformed versus spontaneously-transformed rat cholangiocytes and of corresponding cholangiocarcinomasSchedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinomaSignal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target.Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3Sorafenib exerts anti-glioma activity in vitro and in vivo.STAT3 polymorphism and Helicobacter pylori CagA strains with higher number of EPIYA-C segments independently increase the risk of gastric cancer.Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cellsFunctions of Shp2 in cancer.SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.Liver carcinogenesis: rodent models of hepatocarcinoma and cholangiocarcinoma.Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.EF24 inhibits tumor growth and metastasis via suppressing NF-kappaB dependent pathways in human cholangiocarcinoma.Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma.Tanshinone-1 induces tumor cell killing, enhanced by inhibition of secondary activation of signaling networks.Molecular mechanisms of cholangiocarcinoma.The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma.STAT signaling in the pathogenesis and treatment of myeloid malignancies.Genetic Interactions of STAT3 and Anticancer Drug Development.MiR-204 silencing in intraepithelial to invasive cutaneous squamous cell carcinoma progression.A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer.Inhibition of Autophagy by Chloroquine Enhances the Antitumor Efficacy of Sorafenib in Glioblastoma.Combinatorial anticancer effects of curcumin and sorafenib towards thyroid cancer cells via PI3K/Akt and ERK pathways.Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent MannerSurvey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment.Gamma-aminobutyric acid binds to GABAb receptor to inhibit cholangiocarcinoma cells growth via the JAK/STAT3 pathway.Molecular mechanisms of sorafenib action in liver cancer cells.Model-driven experimental analysis of the function of SHP-2 in IL-6-induced Jak/STAT signaling.A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells.Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells.Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
P2860
Q27000742-CF58AB9D-A694-4CFC-A0F0-BCD515638E25Q28534312-8DE16E31-A8A1-4B3B-B7CC-6254B34D610DQ30453939-B5EBFD3A-BCC6-4DA9-9231-0CE277769D3EQ33686690-5390FAC9-09D1-4AA5-9A76-EC4AF99FBF32Q33863341-D6B4B94E-A30C-4E21-80A7-3F712C42CF4AQ33909909-C74354DC-C53A-4579-BDDE-DE6F8206B2C1Q33994814-41D4EAB3-E05A-4EB0-9DFA-728DFB0B15EAQ34212347-DA4C7649-F50D-4F10-A6F0-6FED76E8815FQ34311704-456AD2F8-31B6-4592-9B43-87F0EBB4D992Q34877852-547C40ED-0BEF-457F-A061-997C81D7B1DBQ34940989-89446E0F-6831-48BF-8308-195AA51F5889Q35404280-61F606F9-D9B8-4C22-86D7-7DCFB2820276Q35414966-F51F1BCA-0CB7-4776-ACDB-BACB403A32ABQ35695315-6677E6FE-F440-4235-AC36-294EC8244C9DQ35761917-7A609414-C5B5-4B7D-9A3A-241372C5890CQ36057452-A54FF23C-7B8A-4924-BF55-E44605A11709Q36376264-B71596D2-751D-4687-ACB5-F6AB1D853A8EQ36629288-D1662F2E-87BD-4FB5-967E-DE7537FBFD9FQ37028411-7812082D-28C6-41E6-979C-5551AB283C0FQ37073574-D2EFF6F1-D3F1-486B-AD44-C33DD08C4749Q37190258-3DB3EC82-51BB-4609-8343-34E05984B386Q37215717-89F1462A-F6BD-4B84-BB9B-3CCDE4829F38Q37309060-EA3792DB-D9FF-4351-B3F4-1C944225D043Q37357080-372BA920-95FC-496D-831E-B96DD5C52F5EQ37878879-8B217AB6-FC68-4CD9-AF57-DECFDFB5FEFCQ37964960-B0A82BBC-4555-4C4E-89DF-91A51B03126DQ38140880-2AA2B978-BC9A-473A-8181-1BF5CDF28D1FQ38198930-F0DBD1DA-76BE-4649-A7DE-CDA259DE5139Q38755893-E3751E94-D429-4007-8991-8A15E205A05EQ38764893-7F077021-0820-4BD4-B58A-00CA8C3DC6E1Q38786782-587EC911-CD55-45DF-8F06-53ED7984CF58Q38841544-36E8E048-26DF-4149-829E-B7C624AFBB10Q38841816-C9A3C4F3-E414-4DE8-A8CE-920672E06C89Q39132926-EAB21686-3E0F-412A-8D8A-8920A217954AQ39272366-427CF0EB-AEBF-4CC3-A61D-266295AB4AD8Q39313526-7361A076-84BC-4E74-8F4D-7B39E36AFBA8Q39328853-F1856499-D6D7-48D1-8D54-426557BEE816Q39366387-659B8380-102E-48C8-ABB4-D827501B2AE1Q39450591-2E38CCFD-FFD8-4676-89AD-7E0E6A768EB7Q39486469-B86A9A04-6DDB-4C1A-9DD8-52F4E9CEFD54
P2860
Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Sorafenib inhibits signal tran ...... he phosphatase shatterproof 2.
@ast
Sorafenib inhibits signal tran ...... he phosphatase shatterproof 2.
@en
type
label
Sorafenib inhibits signal tran ...... he phosphatase shatterproof 2.
@ast
Sorafenib inhibits signal tran ...... he phosphatase shatterproof 2.
@en
prefLabel
Sorafenib inhibits signal tran ...... he phosphatase shatterproof 2.
@ast
Sorafenib inhibits signal tran ...... he phosphatase shatterproof 2.
@en
P2093
P2860
P356
P1433
P1476
Sorafenib inhibits signal tran ...... he phosphatase shatterproof 2.
@en
P2093
Alphonse E Sirica
Boris R A Blechacz
Nathan W Werneburg
Rory L Smoot
Steven F Bronk
P2860
P304
P356
10.1002/HEP.23214
P407
P577
2009-12-01T00:00:00Z